Side-by-side comparison
Eli Lilly and vs Pfizer
As of Sep 25, 2026, P/E is 39.7x for Eli Lilly and vs 37.7x for Pfizer; P/S is 14.0x for Eli Lilly and vs 2.6x for Pfizer; revenue growth is 49.6% for Eli Lilly and vs -0.2% for Pfizer; net margin is 33.5% for Eli Lilly and vs 6.8% for Pfizer.
Key metrics
| Metric | LLY | PFE |
|---|---|---|
| Price | $1,183.46 | $28.67 |
| Market cap | $1.11T | $163.41B |
| P/E | 39.7x (#2) | 37.7x (#1) |
| P/S | 14.0x (#2) | 2.6x (#1) |
| Revenue growth | 49.6% (#1) | -0.2% (#2) |
| Operating margin | — | — |
| Net margin | 33.5% (#1) | 6.8% (#2) |
| Debt / equity | 1.41 (#2) | 0.71 (#1) |
| 1-year return | +63.3% (#1) | +20.7% (#2) |
| Research score | 69/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Eli Lilly and Company (LLY) — Drug Manufacturers—General
- Pfizer Inc. (PFE) — Drug Manufacturers—General